# Lantheus Holdings Inc. (LNTH) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Drug Manufacturers - Specialty & Generic. Price $100.97, market value $6.6 billion.

## Valuation
- **P/E (trailing): 24.2×** (5-yr avg 45.2×, 3-yr avg 17.8×). Lantheus Holdings Inc. trades at 24.2× trailing earnings, well below its own five-year average of 45.2×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 15.8×, lower than trailing, so analysts expect earnings to grow.
- **Price / sales: 4.2×**. Each dollar of revenue is priced at 4.2×.
- **Price / book: 5.0×**. The shares trade at 5.0× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 15.9×**. Enterprise value is 15.9× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Earnings yield: 4.1%**. The inverse of the P/E: 4.1% of the price is earned each year.

## Profitability
- **Gross margin: 60.1%**. Lantheus Holdings Inc. keeps 60.1% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 19.4%**. 19.4% of revenue is left after running the business, a healthy level in most sectors.
- **Net margin: 15.2%**. 15.2% of each dollar of sales reaches the bottom line.
- **Return on equity: 21.4%**. 21.4% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 32.7%**. Return on all capital, debt included, is 32.7%: comfortably above what that capital costs.
- **Return on assets: 12.4%**. Each dollar of assets produces 12.4% of profit.

## Growth
- **Revenue growth (1 yr): 0.5%** (3-yr 18.1%/yr, 5-yr 35.3%/yr). Revenue grew 0.5% over the last year, against 35.3% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -21.8%** (3-yr 104.3%/yr). Earnings per share fell 21.8%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.00**. Debt is 0.00 times equity: a conservative balance sheet.
- **Net debt / EBITDA: net cash**. Lantheus Holdings Inc. holds more cash than debt.
- **Altman Z-score: 5.31**. A Z-score of 5.31 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Lantheus Holdings Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (8 analysts). 8 analysts cover Lantheus Holdings Inc.; the consensus is buy, with an average price target of $107.74 (+7% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 87.6%** (YTD 51.7%, 3-mo -0.0%). The shares are up 87.6% over twelve months including dividends.
- **From 52-week high: -9.7%** (103.3% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 48**. An RSI of 48 is neutral.
- **Beta (1 yr): 0.41** (volatility 35%). Beta of 0.41 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=LNTH · Page: https://foliofundamentals.com/stocks/lnth

Not investment advice.